Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial
Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial
Phase 3 KEYFORM-008 trial evaluated the fixed-dose combination of favezelimab and pembrolizumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL) whose disease has progressed following prior anti-PD-1 therapy.
3期Keyform-008試驗評估了法韋澤利單抗和pembrolizumab的固定劑量組合治療復發或難治性經典霍奇金淋巴瘤（ChL）患者，這些患者在先前的抗PD-1治療後病情已經進展。
Patients currently in this trial may continue on therapy until study completion. KEYFORM-008 is the only Phase 3 study in the KEYFORM clinical development program for which results are not available.
目前參與該試驗的患者可以繼續接受治療直至研究完成。Keyform-008是KeyForm臨床開發計劃中唯一一項尚無結果的3期研究。
The company has made this decision after a thorough evaluation of data from the favezelimab clinical program and will prioritize the development of other candidates in its comprehensive and diversified oncology pipeline. This decision is not based on any concerns about the safety of this fixed-dose combination.
該公司是在對法韋澤利單抗臨床項目的數據進行全面評估後做出這一決定的，並將優先開發其全面和多元化的腫瘤產品線中的其他候選藥物。該決定不是基於對這種固定劑量組合的安全性的任何擔憂。
